ERAS

SEC source: 0001209191-23-002802 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 20,256,222

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

SEC source: 0001209191-22-062536 · doc4.xml · nonDerivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Bristol Survivor?s Trust, Dated October 26, 2019

Disclosed balance after: 20,000

F1 · ownership.nature: The securities reported herein as being purchased were purchased by the Bristol Survivor's Trust Dated October 26, 2019. Such securities may be deemed to be beneficially owned by the Reporting Person, who is the trustee of the Bristol Survivor's Trust Dated October 26, 2019.

SEC source: 0001209191-22-062537 · doc4.xml · nonDerivative · entry 1

Start Valerie Denise Harding · CIK 0001652037 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Start 2006 Trust

Disclosed balance after: 10,000

F1 · ownership.nature: The securities reported herein as being purchased were purchased by the Start 2006 Trust. Such securities may be deemed to be beneficially owned by the Reporting Person, who with her spouse are the co-trustees of the Start 2006 Trust.

SEC source: 0001209191-22-061461 · doc4.xml · nonDerivative · entry 1

Casdin Alexander W. · CIK 0001455228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 443,974

SEC source: 0001209191-22-061352 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 20,196,222

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

SEC source: 0000929638-22-001901 · form4.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · Director

Cormorant Asset Management, LP · CIK 0001583977 · Director

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Director

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,813,246

F1 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F2 · ownership.nature: Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

F3 · ownership.nature: Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund.

SEC source: 0000929638-22-001904 · form4.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · Director

Cormorant Asset Management, LP · CIK 0001583977 · Director

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Director

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,813,246

F1 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F2 · ownership.nature: Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

F3 · ownership.nature: Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund.

SEC source: 0000899243-23-005182 · doc5.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 18,196,216

F1 · kind: Transfer of shares to a trust of which the children of the Reporting Person and his spouse are beneficiaries.

F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

SEC source: 0001209191-22-041388 · doc4.xml · nonDerivative · entry 1

Casdin Alexander W. · CIK 0001455228 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reneo SPV IV LP

Disclosed balance after: 0

F1 · kind: Represents a pro rata distribution in-kind to the partners of Reneo Capital SPV IV LP (Reneo SPV) for no value.

F2 · ownership.nature: Alexander W. Casdin serves as the managing member of Reneo GP LLC, which is the general partner of Reneo SPV. Mr. Casdin exercises voting and dispositive control over the securities held by Reneo SPV and is therefore deemed to be a beneficial owner of securities owned by Reneo SPV. Mr. Casdin disclaims beneficial ownership of the reported securities held by Reneo SPV, except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-013362 · doc1.xml · derivative · entry 3

Chen Bihua · CIK 0001599214 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-21

F4 · ownership.direct: Stock options granted to Ms. Chen, in her capacity as a director of the Issuer.

SEC source: 0001209191-22-039106 · doc4.xml · derivative · entry 1

Varney Michael David · CIK 0001638647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-22-039105 · doc4.xml · derivative · entry 1

Multani Pratik S · CIK 0001586894 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-22-039104 · doc4.xml · derivative · entry 1

Start Valerie Denise Harding · CIK 0001652037 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-22-039103 · doc4.xml · derivative · entry 1

Hambleton Julie · CIK 0001578771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-22-039102 · doc4.xml · derivative · entry 1

Casdin Alexander W. · CIK 0001455228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-22-039101 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-22-025841 · doc4.xml · derivative · entry 1

LIU JEAN I · CIK 0001241357 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-04-24

F1 · derivative.exercise_date: The options shall vest and become exercisable in substantially equal monthly installments over the three years (3) years beginning April 25, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001209191-22-007054 · doc4.xml · derivative · entry 2

Chacko David M. · CIK 0001871801 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 366,125

Underlying: Common Stock · 366,125 shares

Expires 2032-01-31

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001209191-22-007054 · doc4.xml · nonDerivative · entry 1

Chacko David M. · CIK 0001871801 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,498

F1 · balance_after: Includes 1,562 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021.

SEC source: 0001209191-22-007069 · doc4.xml · derivative · entry 2

Garner Ebun · CIK 0001364554 · General Counsel & Corp. Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,110

Underlying: Common Stock · 171,110 shares

Expires 2032-01-31

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001209191-22-007069 · doc4.xml · nonDerivative · entry 1

Garner Ebun · CIK 0001364554 · General Counsel & Corp. Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,890

F1 · balance_after: Includes 990 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021.

SEC source: 0001209191-22-007065 · doc4.xml · derivative · entry 2

Wei Lin · CIK 0001872772 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,100

Underlying: Common Stock · 272,100 shares

Expires 2032-01-31

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001209191-22-007065 · doc4.xml · nonDerivative · entry 1

Wei Lin · CIK 0001872772 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,062

F1 · balance_after: Includes 1,562 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021.

SEC source: 0001209191-22-007062 · doc4.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 791,000

Underlying: Common Stock · 791,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001567619-21-014882 · doc1.xml · nonDerivative · entry 2

Chen Bihua · CIK 0001599214 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,505,553

F1 · price: Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $21.77 to $22.28 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each price.

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4 · ownership.nature: Shares reported herein as purchased on August 10, 2021 represent 200,000 shares purchased by the Master Fund.

F5 · ownership.nature: Represents (i) 1,728,710 shares of Common Stock held by the Master Fund, (ii) 7,716,443 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.

SEC source: 0001567619-21-014882 · doc1.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,305,553

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3 · ownership.nature: Shares reported herein as sold on July 26, 2021 represent 200,000 shares sold by the Master Fund. This sale was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with a purchase of the Common Stock of the Issuer by the Master Fund on July 20, 2021. Ms. Chen and the Issuer have entered into an agreement under which she has remitted to the Issuer $553,000, which represents full payment of the disgorgeable profit arising from such transaction.

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 6

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 93,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 5

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 280,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 4

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 5,067,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 3

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 0

Underlying: Common Stock · 5,135,390 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

SEC source: 0000899243-21-029085 · doc4.xml · nonDerivative · entry 2

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 11,899,360

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-029085 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 20,156,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

SEC source: 0000899243-21-029084 · doc4.xml · nonDerivative · entry 1

Garner Ebun · CIK 0001364554 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900

SEC source: 0000899243-21-029082 · doc4.xml · derivative · entry 4

Casdin Alexander W. · CIK 0001455228 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reneo SPV IV LP

Disclosed balance after: 0

Underlying: Common Stock · 750,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: Alexander Casdin serves as the managing member of Reneo GP LLC, which is the general partner of Reneo Capital SPV IV LP (Reneo SPV). Mr. Casdin exercises voting and dispositive control over the securities held by Reneo SPV and is therefore deemed to be a beneficial owner of securities owned by Reneo SPV. Mr. Casdin disclaims beneficial ownership of the reported securities held by Reneo SPV, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-029082 · doc4.xml · derivative · entry 3

Casdin Alexander W. · CIK 0001455228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

SEC source: 0000899243-21-029082 · doc4.xml · nonDerivative · entry 2

Casdin Alexander W. · CIK 0001455228 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reneo SPV IV LP

Disclosed balance after: 750,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: Alexander Casdin serves as the managing member of Reneo GP LLC, which is the general partner of Reneo Capital SPV IV LP (Reneo SPV). Mr. Casdin exercises voting and dispositive control over the securities held by Reneo SPV and is therefore deemed to be a beneficial owner of securities owned by Reneo SPV. Mr. Casdin disclaims beneficial ownership of the reported securities held by Reneo SPV, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-029082 · doc4.xml · nonDerivative · entry 1

Casdin Alexander W. · CIK 0001455228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

SEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 8

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X Overage, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 944,444 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 7

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X Overage, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,833,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 6

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 944,444 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 5

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,833,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 4

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X Overage, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,750,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029077 · doc4.xml · derivative · entry 3

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,750,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029077 · doc4.xml · nonDerivative · entry 2

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X Overage, L.P.

Disclosed balance after: 5,527,777

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029077 · doc4.xml · nonDerivative · entry 1

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By ARCH Venture Fund X, L.P.

Disclosed balance after: 5,527,777

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.

F3 · ownership.nature: (Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.

SEC source: 0000899243-21-029068 · doc4.xml · nonDerivative · entry 1

Start Valerie Denise Harding · CIK 0001652037 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

SEC source: 0000899243-21-029060 · doc4.xml · nonDerivative · entry 1

Multani Pratik S · CIK 0001586894 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,866

SEC source: 0000899243-21-029053 · doc4.xml · nonDerivative · entry 1

Hambleton Julie · CIK 0001578771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

SEC source: 0001567619-21-013838 · doc1.xml · derivative · entry 5

Chen Bihua · CIK 0001599214 · Director

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,388,887 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F7 · ownership.nature: The Series B-2 Convertible Preferred Stock represented, on an as-converted basis, (i) 262,777 shares of Common Stock held by the Master Fund, and (ii) 1,126,110 shares of Common Stock held by Fund II.

SEC source: 0001567619-21-013838 · doc1.xml · derivative · entry 4

Chen Bihua · CIK 0001599214 · Director

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 4,166,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · price: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Shares of Series A, Series B-1, and Series B-2 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F6 · ownership.nature: The Series B-1 Convertible Preferred Stock represented, on an as-converted basis, (i)788,333 shares of Common Stock held by the Master Fund, and (ii) 3,378,333 shares of Common Stock held by Fund II.